Minimum Information Model for Reporting



Similar documents
PHARMACOVIGILANCE GUIDELINES

POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING E2D

Health Professions Act BYLAWS SCHEDULE F. PART 3 Residential Care Facilities and Homes Standards of Practice. Table of Contents

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

EphMRA Adverse Event Reporting Guidelines 2013

Risk Management Plan (RMP) Guidance (Draft)

TABLE OF CONTENTS CHAPTER 9 PATIENT COUNSELING AND PROSPECTIVE DRUG USE REVIEW REGULATIONS

EphMRA Adverse Event Reporting Guidelines 2015

Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER

Medication Management Guidelines for Nurses and Midwives

Humulin R (U500) insulin: Prescribing Guidance

How To Prevent Medication Errors

STANDARDS AND GUIDELINES TITLE: CIRCULATION DATE: March June 2013 REVISED: June 2013 APPROVAL DATE: July 29, 2013

Understanding Alberta s Drug Schedules

Roles and Responsibilities Policy

Plum Borough School District Nursing Services Department

Standards of Practice for Pharmacists and Pharmacy Technicians

Health Professions Act BYLAWS SCHEDULE F. PART 2 Hospital Pharmacy Standards of Practice. Table of Contents

Professional Standards and Guidance for the Sale and Supply of Medicines

4. Emergency medical treatment due to injury or physical illness. 5. Hospitalization (Medical) due to injury or physical illness

Frequently Asked Questions (FAQs) Treatment Authorization Request (TAR) Restriction on Antipsychotic Medications for the 0-17 Population

A competency framework for all prescribers updated draft for consultation

Custodial Procedures Manual Table of Contents

PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE

Glossary of terms used in Pharmacovigilance

Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies

Medical/Clinical Assistant CIP Task Grid

Agency # REGULATION 9 PHARMACEUTICAL CARE/PATIENT COUNSELING

UW School of Dentistry Comprehensive Medication Policy

Mona Osman MD, MPH, MBA

Unit/Standard Number. Proficiency Level Achieved: (X) Indicates Competency Achieved to Industry Proficiency Level

Keeping patients safe when they transfer between care providers getting the medicines right

Rainbows of Learning School Age Child Care Program At Frankford Township School

Medicines reconciliation on admission and discharge from hospital policy April WHSCT medicines reconciliation policy 1

MARY T. INC. PROGRAM POLICY MANUAL

LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER - SHREVEPORT MEDICAL RECORDS CONTENT/DOCUMENTATION

Requirements for Drug Information Centres

Guideline on good pharmacovigilance practices (GVP)

ADMINISTRATION OF MEDICATIONS POLICY

PHARMACEUTICAL MANAGEMENT PROCEDURES

National Chlamydia Screening Programme September 2012 PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS

CHAPTER CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE)

Recommended guidelines for. schools

Issue: June 2009 PROFESSIONAL STANDARDS AND GUIDANCE FOR THE SALE AND SUPPLY OF MEDICINES

Root cause analysis in context of WHO International Classification for Patient Safety

SAMPLE ANTIMICROBIAL STEWARDSHIP POLICY

a) Each facility shall have a medical record system that retrieves information regarding individual residents.

UNIVERSITY OF WISCONSIN HOSPITAL AND CLINICS DEPARTMENT OF PHARMACY SCOPE OF PATIENT CARE SERVICES FY 2014 October 1 st, 2014

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

NEWFOUNDLAND AND LABRADOR PHARMACY BOARD Standards of Pharmacy Practice. Standards for Hospital Pharmacies

ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Step 5

West Midlands Centre for ADRs. Jeffrey Aronson. Robin Ferner. Side Effects of Drugs Annuals. Editor Meyler s Side Effects of Drugs

247 CMR: BOARD OF REGISTRATION IN PHARMACY

HEALTH REQUIREMENTS & SERVICES: MEDICAL TREATMENT

Adverse Events in Clinical Trials: Definitions and Documentation

VIII. Dentist Crosswalk

S.B. NO.2b72 JAN

PCNE Classification for Drug related problems

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

Pharmacist Administration of Publicly Funded Influenza Vaccine and Claims Submission using the Health Network System

Pain Management Regulations Affect More Than Pain Management Specialists January Of counsel to

SafetyFirst Alert. Errors in Transcribing and Administering Medications

How To Write An Eprescription In Dubai

GUIDELINES ON PREVENTING MEDICATION ERRORS IN PHARMACIES AND LONG-TERM CARE FACILITIES THROUGH REPORTING AND EVALUATION

CONNECTICUT. Downloaded January D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION

Ohio Department of Health Authorization for Student Possession and Use of an Asthma Inhaler In accordance with ORC /3313.

Important Questions Answers Why this Matters: What is the overall deductible? Are there other deductibles for specific services?

Patient Eligibility: Ontarians who are five years of age and older that have a valid Ontario Health Card.

Allergies / Adverse Reactions

Delegation of Services Agreements Change in Regulations

Pharmacy Technician Syllabus 14152

Office of Clinical Standards and Quality / Survey & Certification Group

Please put above in a plastic Ziploc bag with your child s name on it.

Medical Information Checklist For Indian Youth Summer Camp

St Bernard s Catholic School. Administration of Medicine Policy

Outpatient Prescription Drug Benefit

Coverage for: Individual Plan Type: PPO. Important Questions Answers Why this Matters:

Measure #130 (NQF 0419): Documentation of Current Medications in the Medical Record National Quality Strategy Domain: Patient Safety

Important Questions Answers Why this Matters: What is the overall deductible?

11 MEDICATION MANAGEMENT

Adherence to long term therapy and. Dr H. Sefiani CAPM

Ohio Department of Health Authorization for Student Possession and Use of an Epinephrine Autoinjector

NSW Adult Subcutaneous Insulin Prescribing Chart User Guide

MINISTRY OF HIGHER EDUCATION UNIVERSITY OF HAIL COLLEGE OF PHARMACY

Abstral Prescriber and Pharmacist Guide

PPO Hospital Care I DRAFT 18973

Compass Rose Health Plan: High Option Coverage Period: 01/01/ /31/2015

Pharmacy Program Pre-Test

Transcription:

Minimum Information Model for Reporting Dr. H. Sefiani - Pr. R. Soulaymani Bencheikh 1

Background WHO created the Department Safety and vigilances with ambition to integrate all Health Vigilances that allow the interplay various safety issues affecting patients 2

3

Reporting cornerstone of any vigilance system It is important to Collect as many reporting cases as possible (Quantity) Capture information on AEs in a structured manner and to the highest possible quality standards to: Enable causality assessment and preventability evaluation Build an efficient database Support accurate detection and analysis of signals Put in place Risk Minimisation Actions 4

Tools Terminologies, taxonomies and procedures should be harmonized To optimize communication To share data across systems To minimize the risks of inefficient use of resources especially for developing countries 5

Problematic Product used by patient: numerous and complex vigilance systems Each vigilance develop its own system: Specific reporting form Specific information Data collection, data extraction Dissemination Feedback 6

7

Old version: too long and not adapted to all Medicinal Products 8

Specific reporting forms: numerous 9

Limits For vigilance systems: Conception and production of several reporting forms Separated vigilances without any coordination Duplicated systems: logistic, distribution and availibility For reporters Several reporting forms Several interlocutor 10

Underreporting and lack of informations 11

Proposed Solution Adapting reporting form to satisfy reporters and to enhance the performance of the Pharmacovigilance System 12

Intergrated approach Reporting form with minimal common informations Global data base Global analysis Share informations for the consolidated learning around a patient safety incident 13

How?? Analysing the overlaps, redundancies and synergies across reporting and vigilances systems Creating model that will allow the seamless convergence of information 14

Standard reporting form Patient (report Id) AE/Incident Medicinal product: suspected and concomittent Context /circumstances Reporter (to have more information) 15

Invariable data Patient s data Name or initials Age or Date of Birth Sex Weight Origin: urban /rural Profession Relevant medical history Incident/AE data (Yes/No) Clinical description - Severity Date of onset End date Actions taken Outcomes Reporter Name Function : public / health professional Address, phone or email. 16

Health products Variable Data Context/circomstances Medicines, vaccines and combined oral contraceptives Diagnostic radiology products Biological products Medical devices Dietary products and food additives Herbals Homeopathic products Cosmetics products Veterinary products Normal conditions of use Medication errors Treatment failure Drug-drug interactions Dependance Resistance Abuse, misuse Intoxications Toxicomany Defectiveproductsor counterfeit products 17

Health products Variable Data Context/circomstances Medicines, vaccines and combined oral contraceptives Diagnostic radiology products Biological products Medical devices Dietary products and food additives Herbals Homeopathic products Cosmetics products Veterinary products Normal conditions of use Medication errors Treatment failure Drug-drug interactions Dependance Resistance Abuse, misuse Intoxications Toxicomany Defectiveproductsor counterfeit products Before and After marketing Authorization, During medical practice and pharmacoepidemiolgical studies 02/10/2014 WithFirst or EMR/arab without meeting harm 18

Common Items for all Health products Name: brand and commun Indication/ reason for use Dose Route Duration : Start and stop date Action taken (withrawn, dose reduced ) 19

Vaccine Batch number Dose number (1st, 2nd..) Site of administration Vaccination session (public or private..) AEFI category Herbals Medical devices Cosmetics 02/10/2014 First EMR/arab meeting 20

Herbals Vernacular name Common name Part of herb Type of extraction Type of preparation Cosmetics Reason of use Dose (raw material) 02/10/2014 Vaccines First EMR/arab meeting Medical devices 21

Medical devices Brand name Model Type Batch number Location of use The user or manipulator Name and address of the manufacturer Incident (with or without harm) Vaccines Incident category Herbals 02/10/2014 First EMR/arab meeting Cosmetics 22

Cosmetics Site of application Time of application Reason of use Expery date Herbals Medical devices Vaccines 02/10/2014 First EMR/arab meeting 23

Reporting Form in Practice Hard/paper version, must be Unique Attractive, Simple Targeted information requested Short (1 page) Space for answers Possibility to contact reporter for specific items 24

National Pharmacovigilance Centre REPORTING ADVERSE EVENTS OF DRUGS AND OTHER HEALTH PRODUCTS Patient Name: Age: Gender M / / F / / Unknown/ / Weight (Kg): If pregnant, gestation term: Locality/city: Phone number: Adverse(s) events(s) Clinical and paraclinical description of adverse event: Relevant medical history Current medical condition: Comorbidities: Previous history of allergy: yes / / No/ / Unknown / / If yes, please specify which drug: Date of start of reaction: / / / / Date of end of reaction: / / / / Occurrence delay: Hours / / Days / / Months / / Relevant laboratory test: Differential diagnosis eliminated: Action taken: Drug withdrawn / / Dose reduced / / Treatment of reaction (Please specify): Other: Seriousness: Hospitalization / / Prolonged hospitalization / / Outcome: Favorable / / Sequelae / / Not recovered / / Death / / Unknown/ / Drugs and other health products administered by patient Name and form Suspected/ concomitant drug Dosage and route of administration Batch number Date of therapy start Date of therapy end Indication Status of dispensing and use(*) Action taken (**) Please specify if it is: (*) Medical prescription: 1 Self medication: 2 Medication error: 3 Defective product: 4 Drug interaction: 5 (**) Drug withdrawn: a Dose reduced: b Dose increased: c Dose not changed: d Unknown: e If vaccine: Number of administration: Setting of administration: Public sector /_/ Private sector /_/ Vaccination drive /_/ If herbal medicine: Quantity: Part used: Preparation: Infusion / / Decoction / / Soaking / / Other / / Rechallenge with drug or health product: Yes / / No / / Which one : Reccurence of adverse event: Yes / / No / / Please describe: Reporter Name: Tel: Email: Postal address: Physician / / Specialist Dentist / / Pharmacist / / Nurse / / Other healthcare professional: Workplace: Teaching hospital / / Public sector / / Private sector/ / City:. Receive more information about this reporting: Yes / / No / / First EMR/arab meeting Signature To be transmitted by Post / Phone / Fax or Email 02/10/2014 25

Reporting Form in Practice Paper version Attractive, Simple Targeted informations requested Short (1 page) Space for answers Specific form should be available at the PV center Electronic version More exhaustive, but selective Attractive, Simple to fill Common data: first page Links for specific data Maximum: 10 min 26

Electronic version 27

Possible link for all specific data vaccines Herbals Cosmetics Medical devices Diagnostic radiology Biological products - Name of vaccine - Batch number - Dose number - Site of administration - Vaccination session - AEFI category - Vernacular name - Common name - Part of herb - Type of extraction - Type of preparation - Reason of use - Dose (raw material) - Name of product - Site of application - Time of application - Reason of use - Expery date - Manufacturer - Commercial name - Model - Type - Batch number - Location of use - the user or manipulator - name and address of the manufacturer - Incident Dietary products Homeopathic Veterinary 28

TERATOVIGILANCE DRUGS HERBAL COSMETIC Simple form Single form Single window/count 29

Future Vigilances delema Facilitate reporting act for reporters Built Pharmacovigilance performance As complete as possible As polyvalent as possible Integration of vigilances Facing challenges: Not duplicate systems: Rationalize resources Coordination between partners in Vigilances Harmonizing terminologies and definitions Developing a global system for vigilance 30

Thank you 31